Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou Furong Biotechnology
Suzhou, Jiangsu, Chinaforlongbiotech.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Three clinical trials ongoing or recruiting: FL115 monotherapy and combinations (monotherapy recruitment, safety/tolerability/dose escalation in metastatic solid tumors, Phase I); FL115 + PD-1 monoclonal antibody (combination with Sintilimab, Phase 1/2 recruiting for advanced solid tumors); FL115 intravesical and FL115 + BCG (Phase 1/2 recruiting for non-muscle invasive bladder cancer). No published efficacy results yet; safety/tolerability studies underway as of 2025
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Fusion proteinBiological productsCytokine
- Industry
- Biotech
02
Partnerships
Clinical trials with Sintilimab (PD-1 inhibitor)
Beyond the preview
Go deeper on Suzhou Furong Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Furong Biotechnology.